Trough Level and Tacrolimus Variability of Early Converted Once-Daily Tacrolimus: 1-Year Follow-up Study

Comparative Study of OD (Tacrolimus Extended-Release Capsules) Versus Conventional Tacrolimus in Renal Transplant Patients

“…We have observed that there was 100% patient inter-and intra-subject variability in exposure and improves compliance. OD tacrolimus therapeutically is equivalent to twice daily tacrolimus with same therapeutic monitoring as noted in earlier studies [2,3,5].…”

“…Tacrolimus use is associated with a number of adverse effects like nephrotoxicity, neurotoxicity, new onset diabetes, hyperkalemia, hypertension, hyperlipidemia, hypomagnesemia and hyperuricemia [3]. A new formulation of tacrolimus i.e., tacrolimus extended release can be dosed once daily (OD) [4] and may have the ability to simplify immunosuppressive regimens and improve medication compliance translating to better long term allograft survival [5]. OD Tac (tacrolimus extended release capsules) is indicated for prophylaxis of organ rejection in adult patients receiving allogeneic kidney and liver transplants.…”

A Comparative Analysis Of Once-Daily And Twice-Daily Formulation Of Tacrolimus In De Novo Kidney Transplant Recipients

“…Tacrolimus is a milestone immunosuppressive drug in the eld of organ transplantation, as proved by the outcomes of numerous researches [1][2][3]. Tacrolimus has presented a notable decrease in the frequency and severity of acute allograft rejection episodes in solid organ (kidney, liver, and heart) transplants with enhanced graft survival in the long term [1,4].…”

“…Nevertheless, to date, an insu cient number of studies have analyzed the difference in blood-concentration and dosing pro le of once-daily and twice-daily dosing tacrolimus at de novo kidney transplant patients [3,7,9].…”